CLASSIFICATION: GROWTH HORMONE RELEASING PEPTIDE (GHRP)
ACTIVE SUBSTANCE: SERMORELIN
FORM: 2 ML VIAL x 5 MG (LYOPHILIZED POWDER)
ACTIVE HALF-LIFE: 10 TO 20 MINUTES
DOSAGE: MEN 100-300 MCG/DAY
MANUFACTURER: BRITISH DRAGON
British Dragon Sermorelin 5 mg is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically the biologically active fragment GHRH (1-29). Each 2 mL vial contains 5 mg of lyophilized Sermorelin, designed for reconstitution in research settings investigating growth hormone regulation and pulsatile secretion patterns.
Sermorelin acts directly on the pituitary somatotrophs to stimulate endogenous growth hormone release, mimicking the natural GHRH mechanism. For researchers studying the hypothalamic-pituitary axis, this peptide provides a targeted tool for GH pulse manipulation. Explore similar research compounds like Ipamorelin 5 mg or Tesamorelin 5 mg.
As a GHRH analog, Sermorelin represents the N-terminal fragment of endogenous GHRH (1-44), retaining full biological activity while offering a shorter peptide sequence. Unlike GHRP compounds that act on the ghrelin receptor, Sermorelin targets GHRH receptors directly, providing a distinct mechanism for stimulating GH release.
For performance-focused research, Sermorelin is often studied in combination with GHRP analogs to evaluate synergistic effects on GH pulsatility. The 5 mg dosage provides flexibility for both acute and extended research protocols. Researchers may also compare Sermorelin with Tesamorelin to evaluate differences between GHRH analogs.
British Dragon Sermorelin 5 mg is intended for laboratory research only. Not for human consumption or clinical use.
External research on Sermorelin's mechanisms can be explored via PubMed for peer-reviewed studies.
For laboratory research use only. Not for human consumption. Reconstitution and handling must be performed by qualified personnel using sterile techniques.
The standard reconstitution yields a concentration of approximately 1.67-2.5 mg/mL (1670-2500 mcg/mL). For precise dosing, researchers should calculate based on desired mcg per injection volume.
In animal models, Sermorelin is often administered at dosages ranging from 100-500 mcg per injection. Due to its short half-life, multiple daily administrations are common in prolonged studies. Subcutaneous injection is the standard route for systemic absorption research.
Sermorelin is frequently studied alongside GHRP compounds like Ipamorelin or GHRP-2 to evaluate synergistic effects on GH release. This combination can produce amplified GH pulses compared to either peptide alone. For stacking protocols, Ipamorelin 5 mg can be reconstituted and administered concurrently.
Note: Dosages mentioned are for research purposes only. Individual response varies in animal models. Always follow institutional animal care guidelines when conducting in vivo research.
Third-party analytical testing (COA) for British Dragon Sermorelin 5 mg is currently not yet available. Batch-specific assay data, purity analysis, and verification documentation will be published once released.
This product is supplied through the official British Dragon distribution chain and shipped in original manufacturer packaging. The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Store British Dragon Sermorelin 5 mg lyophilized powder in a cool, dry place away from direct light and moisture. Prior to reconstitution, the unopened vial should be kept at controlled room temperature (15-25°C) or refrigerated (2-8°C) for long-term storage. Do not freeze the lyophilized powder, as this may damage the peptide structure.
After reconstitution with bacteriostatic water, the solution must be stored at 2-8°C (refrigerator) and used within 30 days to maintain peptide integrity. Avoid repeated freeze-thaw cycles. Do not use if the solution appears cloudy or contains particulates, or if the vial seal is compromised.
Keep out of reach of children and unauthorized personnel. Follow standard laboratory safety protocols when handling peptides.
Proper storage conditions help maintain research-grade purity and consistent performance across the product's shelf life.
Sermorelin is studied as a GHRH analog that stimulates endogenous growth hormone release via direct action on pituitary somatotrophs. Research applications include GH pulse regulation, hypothalamic-pituitary axis studies, and metabolic investigations in animal models.
Add 2-3 mL of bacteriostatic water to the 5 mg vial, swirling gently until fully dissolved. The resulting concentration will be approximately 1.67-2.5 mg/mL depending on the volume used.
In animal studies, dosages often range from 100-500 mcg per injection, administered once or twice daily. Dosing should be scaled appropriately for the research model and study objectives.
Yes. Sermorelin is commonly studied alongside GHRP compounds such as Ipamorelin or GHRP-2 to evaluate synergistic effects on GH pulsatility and release patterns.
Third-party COA testing is currently pending. British Dragon is committed to publishing batch-specific lab reports as soon as analytical testing is completed and verified.
Please log in to write SERMORELIN 5 MG review.
CLASSIFICATION: GROWTH HORMONE RELEASING PEPTIDE (GHRP)
ACTIVE SUBSTANCE: SERMORELIN
FORM: 2 ML VIAL x 5 MG (LYOPHILIZED POWDER)
ACTIVE HALF-LIFE: 10 TO 20 MINUTES
DOSAGE: MEN 100-300 MCG/DAY
ACNE: RARE
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HBP): NO
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: DRAGON PHARMA